Abstract:We modified a Sabin Oral Poliovirus Vaccine (OPV) vector to permit secretion of the antigens of interest with the goal of improving anti-HIV Env humoral responses in a SHIV mucosal immunization composed of DNA and recombinant OPVs. We evaluated stimulation of systemic and mucosal cell-mediated and humoral immunity in Rhesus macaques by two regimens, both involving a prime with a SHIVBG505 DNA construct producing non-infectious particles formulated in lipid nanoparticles, administered in the oral cavity, and two different viral vector boostings, administered in the oral cavity and intestinally. Group 1 was boosted with rMVA-SHIVBG505, expressing SIV Gag/Pol and HIVBG505 Env. Group 2 was boosted with a SHIVBG505-OPV vaccine including a non-secreting SIVmac239CA-p6-OPV, expressing Gag CA, NC and p6 proteins, and a HIVBG505C1-V2-OPV, secreting the C1-V2 fragment of HIV EnvBG505, recognized by the broadly neutralizing antibody PG16. A time course analysis of anti-SHIV Gag and Env CD4+ and CD8+ T-cell responses in PBMC and in lymph node, rectal, and vaginal MNC was carried out. Both regimens stimulated significant cell-mediated responses in all compartments, with SHIVBG505-OPV immunization stimulating more significant levels of responses than rMVA- SHIVBG505. Boolean analysis of these responses revealed predominantly monofunctional responses with multifunctional responses also present in all tissues. Stimulation of antibody responses was disappointing in both groups with negative anti-SHIV IgG in plasma, and IgA in salivary, rectal and vaginal secretions being restricted to a few animals. After repeated rectal challenge with SHIVBG505, two Group 1 animals remained uninfected at challenge termination. No significant differences were observed in post-infection viral loads between groups. After the acute phase decline, CD4+ T cell percentages returned to normal levels in vaccinated as well as control animals. However, when compared to controls, vaccinate groups had more significant preservation of PBMC and rectal MNC Th17/Treg ratios, considered the strongest surrogate marker of progression to AIDS. We conclude that the vaccine platforms used in this study are insufficient to stimulate significant humoral immunity at the tested doses and schedule but sufficient to stimulate significant mucosal and systemic cell-mediated immunity, impacting the preservation of key Th17 CD4+ T cells in blood and rectal mucosa.

Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene.

Comparative Immunogenicity In Rhesus Monkeys Of Dna Plasmid, Recombinant Vaccinia Virus, And Replication-Defective Adenovirus Vectors Expressing A Human Immunodeficiency Virus Type 1 Gag Gene

Preclinical Evaluation of Cellular Immune Responses Elicited by a Polyvalent DNA Prime/protein Boost HIV-1 Vaccine

Evaluation Of Novel Human Immunodeficiency Virus Type 1 Gag Dna Vaccines For Protein Expression In Mammalian Cells And Induction Of Immune Responses

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

Impact of Recombinant VSV-HIV Prime, DNA-Boost Vaccine Candidates on Immunogenicity and Viremia on SHIV-Infected Rhesus Macaques

Cross-Subtype Antibody and Cellular Immune Responses Induced by A Polyvalent Dna Prime-Protein Boost Hiv-1 Vaccine in Healthy Human Volunteers

Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vector

Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV gag conserved elements in macaques

Vaccine-Induced Immunity in Baboons by Using DNA and Replication-Incompetent Adenovirus Type 5 Vectors Expressing a Human Immunodeficiency Virus Type 1 Gag Gene

Immunization of Rhesus Macaques with a Polyvalent DNA Prime/protein Boost Human Immunodeficiency Virus Type 1 Vaccine Elicits Protective Antibody Response Against Simian Human Immunodeficiency Virus of R5 Phenotype

DNA Vaccination As Anti—Human Immunodeficiency Virus Immunotherapy in Infected Chimpanzees

Stabilized HIV-1 envelope immunization induces neutralizing antibodies to the CD4bs and protects macaques against mucosal infection

Vaccine Protection Against Acquisition of Neutralization-Resistant Siv Challenges in Rhesus Monkeys

Heterologous prime-boost vaccination drives early maturation of HIV broadly neutralizing antibody precursors in humanized mice

Oral Vaccination Approaches for Anti-SHIV Immunity

Polyvalent DNA Prime and Envelope Protein Boost HIV-1 Vaccine Elicits Humoral and Cellular Responses and Controls Plasma Viremia in Rhesus Macaques Following Rectal Challenge with an R5 SHIV Isolate.

Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques

Optimal Expression, Function, and Immunogenicity of an HIV-1 Vaccine Derived from the Approved Ebola Vaccine, rVSV-ZEBOV

Engineered deletions of HIV replicate conditionally to reduce disease in nonhuman primates

3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope–specific plasma cells and humoral immunity in nonhuman primates